🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,071 results for “tablet” Clear

  1. A study in healthy people to compare two tablet formulations of pramipexole

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  2. A study in healthy people to see how zongertinib is taken up into the blood when given as tablets made by two different manufacturers

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  3. A study in healthy people to test how empagliflozin is taken up in the body when taken as a whole tablet or dissolved in water and mixed with food

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  4. A study to compare the amount of milvexian in blood when given as pediatric and adult tablet formulations, to assess the effect of food intake on the absorption of pediatric milvexian tablet formulation in healthy adult participants and to assess the acceptability of different milvexian formulations.

    Janssen-Cilag International N.V.

    atherothrombotic and thromboembolic disorders

    phase 1 other active

    1 trial

  5. A study to establish the bioequivalence of free acid tafamidis 61 mg capsule and tablet, and evaluate the safety and tolerability of the 61 mg tablet in healthy adults

    Pfizer Australia Pty Ltd

    Transthyretin amyloidosis

    phase 1 other active

    1 trial

  6. A study to investigate how different tablet types of balinatunfib and food will influence the absorption of balinatunfib in blood in healthy adult participants

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 1 other active

    1 trial

  7. A study to learn about how a new nurandociguat tablet is absorbed and processed in the body compared to an old tablet and how food affects the way the new tablet is absorbed and processed in the body

    Bayer AG

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  8. A study to learn about how itraconazole affects the level of emodepside in the blood when emodepside is given as a new type of tablet to healthy participants

    Bayer AG

    Soil-transmitted helminth infection, Onchocerciasis (river blindness)

    phase 1 other active

    1 trial

  9. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  10. A study to learn about the amount of asundexian in the blood when healthy participants take different types of asundexian tablets

    Bayer AG

    Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack

    phase 1 other active

    1 trial

  11. A three-part trial in healthy volunteers to find out how long icotrokinra stays in and acts on the body when administered as different tablet formulations and under different food conditions

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  12. A two-part trial in healthy volunteers to find out how long JNJ-77242113 stays in and acts on the body when administered as different tablet formulations and under different food and water conditions, and to assess the acceptability profile (taste, palatability, and smell) of JNJ-77242113 formulations.

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  13. ABI-4334 Tablet

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  14. AG10 oral tablet

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy, Transthyretin-Related

    phase 1 small molecule completed

    1 trial

  15. AKB-6548 tablet, reference formulation given in the fasted state

    Akebia Europe Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  16. AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TABLETS (TEST FORMULATION) VS. EQUAL DOSE OF INTUNIV® PROLONGED-RELEASE TABLETS (REFERENCE FORMULATION) IN HEALTHY MALE VOLUNTEERS UNDER FASTING CONDITIONS

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Study performed on healthy volunteers.

    phase 1 other active

    1 trial

  17. ARAVA® 20 mg tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  18. AVICOD 200 MG Film Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Bioequivalence

    phase 1 small molecule active

    1 trial

  19. Alendronate Sodium Tablets 70mg

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  20. Alprazolam Extended-Release 3 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  21. Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）

    The First People's Hospital of Lianyungang

    Depressive Disorder

    phase 1 small molecule completed

    1 trial

  22. An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered Alone and in Combination with Itraconazole Capsules in Healthy Adult Female and Male Participants

    AstraZeneca AB

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  23. An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Empagliflozin Tablets 25 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Jardiance (Empagliflozin) 25 mg film-coated tablets, Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein Germany, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Diabetes

    phase 1 other active

    1 trial

  24. An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Ivacaftor film coated tablets 150 mg of Sun Pharmaceutical Industries Ltd, India with Kalydeco (Ivacaftor) 150 mg film-coated tablets, Marketing Authorisation Holder: Vertex Pharmaceuticals (Ireland) Limited Unit 49, Block F2, Northwood Court, Santry, Dublin 9, D09 T665, Ireland, in healthy adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    Cystic Fibrosis

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources